WSC 2026 | One big question with Mike Sharma: how will asundexian transform secondary stroke prevention?

So, you know, our goal with secondary stroke prevention is to bring the risk of another stroke as close to zero as possible. And I think this is a big advance. What I hope to see in five years is that everyone who can benefit from asundexian is taking it, which is a large number of people. Now, in order to get there, we as clinicians will need to change our thinking. Right now, it’s really based on an assessment of risk. A very different way of thinking is, will this patient benefit from it? Because I know there isn’t additional harm. Now, that may sound straightforward, but we’re going to have to reorder our brains to get there. The other thing is being able to communicate trial results, expectations clearly to patients. So patients know what to expect, know that this doesn’t magically eliminate bleeding, because again, it may happen to people who are taking no agents at all, and what course of action to take if that occurs. So my hope is, in five years, we’ll have many patients on asundexian, we’ll have lower rates of recurrent stroke, lower costs to human beings, lower costs to the healthcare system and society, and get toward our goal of a zero chance of recurrence.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.